Bahraini MS STIM1/ORAI1 cohort 2025 — First patient-cohort SOCE-pathway dysregulation in autoimmune CNS disease (H5b cross-condition anchor)

One-paragraph summary

Case-control study of 45 Bahraini multiple sclerosis (MS) patients (split into early-stage and late-stage) and 45 matched healthy controls. ELISA + real-time PCR analysis of three SOCE-pathway molecules: SARAF (store-operated calcium entry-associated regulatory factor), STIM1, and ORAI1. Findings: serum SARAF significantly elevated in early MS (192.26 ± 47.00 pg/mL) and further elevated in late MS (341.47 ± 96.19 pg/mL) vs controls (129.82 ± 30.82 pg/mL; P < 0.001). Stage-progressive elevation. SARAF expression markedly increased (3.83 vs 1; P < 0.0001); STIM1 expression markedly reduced (0.43 vs 1; P < 0.0001); ORAI1 expression markedly reduced (0.30 vs 1; P < 0.0001). Intracellular calcium elevated in both early and late MS stages. The first direct patient-cohort evidence that the STIM1/Orai1 SOCE pathway is dysregulated in an autoimmune CNS disease. Cross-condition anchor for H5b at the CA-I1 intersection. Proposes SARAF as candidate biomarker for MS progression and SOCE-pathway components as therapeutic targets.

Claims as triples

• multiple_sclerosis — elevates → serum_SARAF_level [evidence: case-control n=45+45, P<0.001 with stage progression; confidence: emerging]
• multiple_sclerosis — reduces → STIM1_expression [evidence: same study, P<0.0001; confidence: emerging]
• multiple_sclerosis — reduces → ORAI1_expression [evidence: same study, P<0.0001; confidence: emerging]
• multiple_sclerosis — elevates → intracellular_calcium [evidence: same study; confidence: emerging]
• serum_SARAF_level — biomarker_for → multiple_sclerosis_stage [evidence: stage-progressive elevation; confidence: emerging]
• SARAF — modulates → store_operated_calcium_entry [evidence: known SOCE regulator (review evidence); confidence: established]

Methods note

Case-control design with 45 MS + 45 HC. ELISA for serum SARAF. RT-PCR for STIM1 + ORAI1 expression (presumably PBMCs or whole-blood RNA). Intracellular calcium imaging methodology not specified in abstract. Stage stratification (early vs late MS) within the MS arm. Bahraini population — cross-ethnic generalizability question but supports cross-condition principle.

Limitations

• Modest sample size (n=45+45)
• ELISA + PCR; not functional SOCE measurement directly (intracellular calcium measured but methodology details limited in abstract)
• Cell-type-specific expression not resolved (PBMC vs lymphocyte subsets vs MC)
• Cross-sectional, not longitudinal — stage-progressive interpretation is inferred
• MS, not FM — FM-direct evidence absent
• The direction of effect is surprising: SARAF up, STIM1/Orai1 expression DOWN, but intracellular calcium UP. The mechanism may involve compensatory dysregulation (SARAF upregulation as feedback to attenuate calcium leak; STIM1/Orai1 downregulation as feedback) or differential cellular compartments. Functional interpretation requires additional follow-up.

Open questions raised

• Q-IBC-13 (new): Does the same SOCE-pathway dysregulation pattern (SARAF up + STIM1/ORAI1 expression down + intracellular calcium up) operate in FM patient PBMCs or patient-derived MC? Direct functional SOCE assay in FM-IgG-positive vs FM-IgG-negative cohorts. Q-IBC-2 implementation candidate.
• Q-IBC-14 (new): Is SARAF a candidate FM stratification biomarker analogous to its role in MS staging? Serum SARAF in FM-IgG-positive cohort vs FM-IgG-negative cohort vs healthy controls.
• Q-IBC-15 (new): Does the H5b genetic-risk-module + functional SOCE phenotype correlate with the SARAF expression dysregulation? Joint genotyping + functional SOCE + SARAF ELISA on one cohort would resolve.

Triangulation notes

• Establishes the H5b CA-I1 substrate is patient-measurable in an autoimmune CNS disease. Until now, the SOCE-in-MC framing was project-internal (mechanism description) — this study makes the SOCE-pathway dysregulation a measurable patient phenotype in MS, which is the closest immune-tolerance-failure cross-condition to the FM-autoimmune subtype.
• Cross-condition transfer hypothesis: if MS shows SARAF-up + STIM1/Orai1-expression-down dysregulation in patient PBMCs, FM-IgG-positive patients are the candidate analogous group. The IL2RA+CTLA4+MS connection in the H5b module (Treg dysfunction shared between FM-autoimmune and MS) provides the conceptual frame.
• HERV-W ↔ FM/MS bridge B7 gains a new layer: SOCE-pathway dysregulation is mechanistically downstream of HERV-W-driven type-I-IFN activation (cGAS-STING). The two mechanisms — HERV-W-IFN and STIM1/Orai1-SOCE — may converge in MS, predicting they should also converge in HERV-W-positive FM patients.
• Reframes the Sanchez 2025 MRGPRX2 mechanism: if FM-IgG-positive patients also have STIM1/Orai1 expression dysregulation, the per-unit-FM-IgG MC degranulation response would be modulated — directly testable via patient-derived MC + MRGPRX2 stimulation + calcium imaging.

Bridges

• B-Gen-3 advance: H5b ↔ CA-I1 bridge gains first patient-cohort evidence in autoimmune CNS disease. Bridge advances bridging → bridging-with-cross-condition-patient-evidence.
• New candidate bridge B-IBC-SARAF (NEW): SARAF as candidate cross-condition staging biomarker. SARAF in FM patient samples would be the natural cross-condition validation test.

Ontology additions needed

• Consider adding SARAF as new molecule entity (SOCE regulatory factor)
• Consider adding serum_SARAF_level as new biomarker entity
• Consider adding intracellular_calcium as new biomarker entity (may already exist)

Chain-map update

• H5b CA-I1 layer: gains patient-cohort cross-condition anchor (MS). The intersection moves from "mechanism + drug candidate" toward "mechanism + drug candidate + measurable patient phenotype in cross-condition." FM-direct equivalent (Q-IBC-2 functional SOCE in FM patients) is the next operational step.

Confidence-tier framing

• Serum SARAF elevated in MS: emerging (single cohort, modest n; replication needed)
• SARAF as MS staging biomarker: emerging (stage-progressive pattern observed)
• SOCE-pathway dysregulation as autoimmune-disease substrate: emerging (MS evidence)
• Cross-condition extension to FM: bridging (predicted by H5b; no FM-direct evidence yet)
• B-Gen-3 closure: partial (cross-condition patient evidence; FM-direct gate still open)